470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

S.Glück; C.Lobo; G.Lopes; A.Castrellon; J.Hurley; I.Reis; S.Richman; O.Silva; J.Slingerland; C.Welsh

首页> 外文期刊>European Journal of Cancer Supplements >470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

【24h】

470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

机译：470纳博-紫杉醇，贝伐单抗和吉西他滨联合作为HER2阴性转移性乳腺癌患者的一线治疗的II期研究的最终结果

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第3期|共1页
作者
S.Glück; C.Lobo; G.Lopes; A.Castrellon; J.Hurley; I.Reis; S.Richman; O.Silva; J.Slingerland; C.Welsh;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. [J] . Lobo C, Lopes G, Baez O, Breast cancer research and treatment. . 2010,第2期

机译：纳布-紫杉醇，贝伐单抗和吉西他滨作为HER2阴性转移性乳腺癌患者的一线治疗的II期研究的最终结果。
2. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J] . Christopher Lobo, Gilberto Lopes, Odalys Baez, Breast Cancer Research and Treatment . 2010,第2期

机译：纳布紫杉醇，贝伐单抗和吉西他滨作为HER2阴性转移性乳腺癌患者的一线治疗的II期研究的最终结果
3. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J] . Salvador J., Manso L., de la Haba J., Clinical & translational oncology : . 2015,第2期

机译：紫杉醇，贝伐单抗和吉西他滨作为一线治疗HER2阴性转移性乳腺癌患者的II期研究的最终结果
4. Gemcitabine + Cisplatin Combination Electrochemotherapy for Triple Negative Breast Cancers: An in vitro Model Study [C] . R. Sundararajan, V. Raman, V. Masterson World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：Gemcitabine +顺铂组合电化学疗法三重阴性乳腺癌：体外模型研究
5. Enhancement of Gemcitabine and Paclitaxel Uptake and Retention in Metastatic Cancer Cells: A Novel Targeted Combination Delivery Approach to Eliminate Breast Cancer in Blood and Lymph [D] . Yu, Jesse. 2020

机译：吉西他滨和紫杉醇吸收的增强和转移性癌细胞的保留：一种小型靶向组合递送方法，消除血液和淋巴中的乳腺癌
6. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial [O] . Denise A. Yardley, Adam Brufsky, Robert E. Coleman, 2016

机译：勘误：‘每周II / III期nab-紫杉醇联合吉西他滨或卡铂与吉西他滨/卡铂作为转移性三阴性乳腺癌患者的一线治疗（tnAcity研究）：一项随机对照试验的研究方案
7. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer [O] . Vrdoljak E., Marschner N., Zielinski C., 2016

机译：贝伐单抗治疗HER2阴性的局部复发/转移性乳腺癌的一线贝伐单抗治疗进展后的TANIA TANIA随机III期临床试验的最终结果

470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅